Progress in neurobiologyOct 12, 2026

How a Protein Network Involving Parkin and Cell Cleanup Controls Cell Death in Parkinson's Disease and Possible Treatments

Longevity & Aging Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 13, 2026

Abstract

Neuroinflammation and dysregulated programmed cell death are central pathological drivers of Parkinson's Disease.

PANoptosis is a type of programmed cell death that can trigger apoptosis, pyroptosis, and necroptosis simultaneously.
The NLRP3 inflammasome acts as a core molecular hub for initiating PANoptosis.
Parkin interacts with NLRP3 and mediates a specific type of ubiquitination that targets NLRP3 for degradation.
This degradation process occurs through chaperone-mediated autophagy, which helps to preserve the survival of dopaminergic neurons.
The review discusses the functional interactions between the Parkin-CMA-NLRP3-PANoptosis signaling axis and other pathological events associated with Parkinson's Disease.
Challenges such as molecular regulatory details and the permeability of candidate agents across the blood-brain barrier are identified as critical bottlenecks for developing effective treatments.

Simplified

Parkinson's Disease (PD) is a common neurodegenerative disorder. Existing clinical interventions merely relieve symptoms and cannot reverse progressive neuronal injury. Neuroinflammation and dysregulated programmed cell death are central pathological drivers of PD. PANoptosis is an integrated pan-programmed cell death, can simultaneously trigger apoptosis, pyroptosis and necroptosis, with the NOD‑like receptor family pyrin domain‑containing 3 (NLRP3) inflammasome serving as a core molecular hub for PANoptosis initiation. Apart from its well‑characterized role in mitophagy, Parkin directly interacts with NLRP3 and mediates K63‑linked ubiquitination at the NLRP3‑K353 residue. This post‑translational modification targets NLRP3 for degradation through chaperone‑mediated autophagy (CMA), which suppresses excessive PANoptosis and preserves dopaminergic neuron survival. This review systematically delineates the molecular framework of the Parkin‑CMA‑NLRP3‑PANoptosis signaling axis. We further discuss its functional crosstalk with canonical PD‑associated pathological events, including α‑synuclein (α‑syn) aggregation and mitochondrial dysfunction, and summarize translational progress of small‑molecule compounds and gene therapies targeting individual components within this cascade. Critical bottlenecks are also addressed, such as unresolved molecular regulatory details, limitations of preclinical animal models, poor blood‑brain barrier permeability of candidate agents, and obstacles for early therapeutic intervention. This work intends to uncover promising targets for PD disease‑modifying treatments and support the advancement of precision therapeutic strategies.

Full Text

Full text is available at the source.

View Full Text ↗

How a Protein Network Involving Parkin and Cell Cleanup Controls Cell Death in Parkinson's Disease and Possible Treatments

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief